Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.

George, Mridula A; Qureshi, Sadaf; Omene, Coral; Toppmeyer, Deborah L; Ganesan, Shridar

George, Mridula A; Qureshi, Sadaf; Omene, Coral; Toppmeyer, Deborah L; Ganesan, Shridar.

Afiliación

George MA; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States.
Qureshi S; Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States.
Omene C; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States.
Toppmeyer DL; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States.
Ganesan S; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States.

Front Oncol ; 11: 693104, 2021.

Article en En | MEDLINE | ID: mdl-34327137

Palabras clave

CDK4/6 cell cycle inhibitors; CDK4/6 inhibitors in breast cancer; abemaciclib; hormone receptor (HR); metastatic breast cancer; palbociblib; ribociclib

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google